Neurotech International Ltd (NTI) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.007x

Based on the latest financial reports, Neurotech International Ltd (NTI) has a cash flow conversion efficiency ratio of -0.007x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-38.33K ≈ $-27.12K USD) by net assets (AU$5.88 Million ≈ $4.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Neurotech International Ltd (NTI) balance sheet quality index to measure how much of total assets are equity-financed.

Neurotech International Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Neurotech International Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Neurotech International Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Neurotech International Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Neurotech International Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Talius Group Ltd.
AU:TAL
-0.424x
Lifestyle Global Enterprise
TWO:8066
0.102x
Crown Lifters Limited
NSE:CROWN
0.022x
HPMT Holdings Bhd
KLSE:5291
0.144x
SAGTEC GLOBAL LIMITED Ordinary shares
NASDAQ:SAGT
0.281x
Les Hôtels de Paris SA
PA:HDP
1.495x
Peak Processing Limited
AU:PKP
0.576x
Natural Alternatives International
NASDAQ:NAII
-0.094x

Annual Cash Flow Conversion Efficiency for Neurotech International Ltd (2015–2025)

The table below shows the annual cash flow conversion efficiency of Neurotech International Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see NTI market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$2.95 Million
≈ $2.09 Million
AU$-9.02 Million
≈ $-6.39 Million
-3.054x -690.85%
2024-06-30 AU$11.90 Million
≈ $8.42 Million
AU$-4.60 Million
≈ $-3.25 Million
-0.386x +75.78%
2023-06-30 AU$3.96 Million
≈ $2.80 Million
AU$-6.32 Million
≈ $-4.47 Million
-1.594x +22.85%
2022-06-30 AU$1.43 Million
≈ $1.01 Million
AU$-2.96 Million
≈ $-2.09 Million
-2.067x -244.48%
2021-06-30 AU$3.86 Million
≈ $2.73 Million
AU$-2.32 Million
≈ $-1.64 Million
-0.600x -156.78%
2020-06-30 AU$-646.29K
≈ $-457.29K
AU$-682.83K
≈ $-483.15K
1.057x +112.36%
2019-06-30 AU$297.41K
≈ $210.44K
AU$-2.54 Million
≈ $-1.80 Million
-8.551x -1095.71%
2018-06-30 AU$4.23 Million
≈ $2.99 Million
AU$-3.03 Million
≈ $-2.14 Million
-0.715x +1.59%
2017-06-30 AU$4.30 Million
≈ $3.04 Million
AU$-3.12 Million
≈ $-2.21 Million
-0.727x -1239.04%
2016-06-30 AU$14.48 Million
≈ $10.25 Million
AU$-785.79K
≈ $-555.99K
-0.054x +91.75%
2015-12-31 AU$1.29 Million
≈ $916.07K
AU$-851.21K
≈ $-602.29K
-0.657x --

About Neurotech International Ltd

AU:NTI Australia Biotechnology
Market Cap
$13.99 Million
AU$19.77 Million AUD
Market Cap Rank
#26170 Global
#1179 in Australia
Share Price
AU$0.02
Change (1 day)
-11.76%
52-Week Range
AU$0.01 - AU$0.02
All Time High
AU$0.48
About

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxati… Read more